References 1 Blackstone EA , Joseph PF . The economics of biosimilars . Am Health Drug Benefits . 2013 ; 6 ( 8 ): 469 – 78 . 2 Jacobs I et al . Patient attitudes and understanding about biosimilars : An international cross-sectional survey . Patient Prefer Adherence 2016 ; 10 : 937 – 48 . 3 Frantzen L et al . Patients ’ information and perspectives on biosimilars in rheumatology : A French nation-wide survey . Jt Bone Spine 2019 ; 86 ( 4 ): 491 – 6 . 4 US FDA Web site . www . fda . gov / drugs / biosimilars / biosimilarproduct-information ( accessed August 2020 ). 5 Mulcahy AW , Hlavka JP , Case SR . Biosimilar cost savings in the United States : Initial experience and future potential . Rand Health Q . 2018 ; 7 ( 4 ): 3 . 6 Vulto AG , Jaquez OA . The process defines the product : what really matters in biosimilar design and production ?. Rheumatology ( Oxford ) 2017 ; 56 ( suppl _ 4 ): iv14-iv29 . 7 Noh SM , Sathyamurthy M , Lee GM . Development of recombinant Chinese hamster ovary cell lines for therapeutic protein production . Curr Opin Chem Eng 2013 ; 2 ( 4 ): 391 – 7 . 8 Ingrasciotta Y et al . Safety of biologics , including biosimilars : Perspectives on current status and future direction . Drug Saf 2018 ; 41 ( 11 ): 1013 – 22 . 9 Tjalma W , Huizing MT , |
Papadimitriou K . The smooth and bumpy road of trastuzumab administration : from intravenous ( IV ) in a hospital to subcutaneous ( SC ) at home . Facts Views Vis ObGyn 2017 ; 9 ( 1 ): 51 – 5 . 10 AJMC . Ahead of the arrival of US biosimilar trastuzumab , FDA approves subcutaneous herceptin . 2019 . www . centerforbiosimilars . com / news / ahead-of-the-arrival-ofus-biosimilar-trastuzumabfda-approves-subcutaneousherceptin ( accessed August 2020 ). 11 Papadimitriou K et al . The socio-economical impact of intravenous ( IV ) versus subcutaneous ( SC ) administration of trastuzumab : future prospectives . Facts Views Vis ObGyn 2015 ; 7 ( 3 ): 176 – 80 . 12 Jackisch C et al . Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer : Final analysis of the HannaH Phase 3 randomized clinical trial . JAMA Oncol 2019 ; 5 ( 5 ): 1 – 5 . 13 Denys H et al . Safety and tolerability of subcutaneous trastuzumab at home administration , results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer . Breast Cancer Res Treat 2020 ; 181 ( 1 ): 97 – 105 . 14 Pivot X et al . Patients ’ preference of trastuzumab administration ( subcutaneous versus intravenous ) in HER2- positive metastatic breast cancer : |
Results of the randomised MetaspHer study . Eur J Cancer 2017 ; 82:230 – 6 . 15 Locke KW , Maneval DC , LaBarre MJ . ENHANZE ® drug delivery technology : a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20 . Drug Deliv 2019 ; 26 ( 1 ): 98 – 106 . 16 Declerck P et al . Monoclonal antibody biosimilars in oncology : Critical appraisal of available data on switching . Clin Ther 2018 ; 40 ( 5 ): 798 – 809 . e2 . 17 European Generic Medicines Association . The future of pharmaceuticals : Generic medicines enhancing pharmaceutical competition and ensuring healthcare sustainability issues . http :// 198.170.119.137 / doc / ega _ FuturePharmaceuticals . pdf . 2007 . 18 US FDA . FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin ’ s lymphoma . https :// www . fda . gov / drugs / fdaapproves-truxima-biosimilarrituxan-non-hodgkinslymphoma . 2018 . 19 Larsen FO et al . Safety and feasibility of home-based chemotherapy . Dan Med J 2018 ; 65 ( 5 ): A5482 . 20 Royal Marsden . Administration of subcutaneous trastuzumab . Pharmacy 2020 . https :// shared-d7-royalmarsdenpublicne-live . s3-eu-west-1 . amazonaws . com / files _ trust / s3fspublic / Step-by-step Instructions |
for Administering Subcutaneous Trastuzumab Injections FINAL v9 _ 0 . pdf ( accessed August 2020 ). 21 Thomaidou E , Ramot Y . Injection site reactions with the use of biological agents . Dermatol Ther 2019 ; 32 ( 2 ): 1 – 4 . 22 Corominas M , Gastaminza G , Lobera T . Hypersensitivity reactions to biological drugs . J Investig Allergol Clin Immunol 2014 ; 24 ( 4 ): 212 – 25 . 23 Funakoshi T , Suzuki M , Muss HB . Infection risk in breast cancer patients treated with trastuzumab : a systematic review and meta-analysis . Breast Cancer Res Treat 2015 ; 149 ( 2 ): 321 – 30 . 24 US FDA . How consumers can report an adverse event or serious problem to the FDA . 2018 . www . fda . gov / safety / reporting-serious-problems-fda / how-consumers-can-reportadverse-event-or-seriousproblem-fda ( accessed August 2020 ). |
34 | 2021 | hospitalpharmacyeurope . com |